Loading...

Shweta Joshi

Title(s)Assistant Professor, Cancer Center
SchoolHealth Sciences
Address9500 Gilman Drive #0815
La Jolla CA 92093
Phone858-822-7580
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    The primary goal of our research is to understand molecular mechanisms regulating tumor growth, inflammation and metastasis. Our laboratory is focused on the study of signaling cascades that regulate recruitment and activation of immunosuppressive macrophages in solid tumors with special focus on neuroblastoma and pancreatic adenocarcinoma.

    Collapse Research 
    Collapse Research Activities and Funding
    Myeloid Syk promotes tumor immunosuppression and inhibits anti-tumor adaptive immunity
    NIH K22CA229594Dec 1, 2019 - Nov 30, 2022
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity. Cell Discov. 2020; 6:49. Burgoyne AM, Vann KR, Joshi S, Morales GA, Vega FM, Singh A, Pal D, Merati AB, Kutateladze TG, Durden DL. PMID: 32793389.
      View in: PubMed   Mentions:
    2. Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions. Cancers (Basel). 2020 Jul 25; 12(8). Joshi S. PMID: 32722460.
      View in: PubMed   Mentions:
    3. Macrophage Syk-PI3K? Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Mol Cancer Ther. 2020 03; 19(3):755-764. Joshi S, Liu KX, Zulcic M, Singh AR, Skola D, Glass CK, Sanders PD, Sharabi AB, Pham TV, Tamayo P, Shiang D, Dinh HQ, Hedrick CC, Morales GA, Garlich JR, Durden DL. PMID: 31974273.
      View in: PubMed   Mentions: 1     Fields:    
    4. SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer. Mol Cancer Ther. 2019 06; 18(6):1036-1044. Joshi S, Singh AR, Liu KX, Pham TV, Zulcic M, Skola D, Chun HB, Glass CK, Morales GA, Garlich JR, Durden DL. PMID: 31018997.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    5. Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System. J Oncol. 2019; 2019:5245034. Joshi S, Durden DL. PMID: 30853982.
      View in: PubMed   Mentions:
    6. Erratum to: Vascular Permeability and Remodelling Coincide with Inflammatory and Reparative Processes after Joint Bleeding in Factor VIII-Deficient Mice. Thromb Haemost. 2019 09; 119(9):1546. Cooke EJ, Zhou JY, Wyseure T, Joshi S, Bhat V, Durden DL, Mosnier LO, von Drygalski A. PMID: 30071568.
      View in: PubMed   Mentions:    Fields:    
    7. Vascular Permeability and Remodelling Coincide with Inflammatory and Reparative Processes after Joint Bleeding in Factor VIII-Deficient Mice. Thromb Haemost. 2018 06; 118(6):1036-1047. Cooke EJ, Zhou JY, Wyseure T, Joshi S, Bhat V, Durden DL, Mosnier LO, von Drygalski A. PMID: 29847841.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    8. Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication. J Biol Chem. 2018 04 20; 293(16):5808-5820. Campbell GR, Bruckman RS, Herns SD, Joshi S, Durden DL, Spector SA. PMID: 29475942.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    9. Rac2 is required for alternative macrophage activation and bleomycin induced pulmonary fibrosis; a macrophage autonomous phenotype. PLoS One. 2017; 12(8):e0182851. Joshi S, Singh AR, Wong SS, Zulcic M, Jiang M, Pardo A, Selman M, Hagood JS, Durden DL. PMID: 28817691.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    10. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Mol Cancer Ther. 2016 11; 15(11):2553-2562. Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL. PMID: 27496136.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    11. Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12)?V-Ha-Ras transgenic mouse glioma model. Cancer Cell Int. 2014; 14(1):105. Singh AR, Joshi S, George E, Durden DL. PMID: 25425962.
      View in: PubMed   Mentions:
    12. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1a and HIF2a stability and tumor growth, angiogenesis, and metastasis. Mol Cancer Res. 2014 Oct; 12(10):1520-31. Joshi S, Singh AR, Zulcic M, Durden DL. PMID: 25103499.
      View in: PubMed   Mentions: 29     Fields:    Translation:AnimalsCells
    13. Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. J Pediatr Hematol Oncol. 2014 Aug; 36(6):451-7. Hartman LL, Crawford JR, Makale MT, Milburn M, Joshi S, Salazar AM, Hasenauer B, VandenBerg SR, MacDonald TJ, Durden DL. PMID: 24309609.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    14. PTEN and PI-3 kinase inhibitors control LPS signaling and the lymphoproliferative response in the CD19+ B cell compartment. Exp Cell Res. 2014 Sep 10; 327(1):78-90. Singh AR, Peirce SK, Joshi S, Durden DL. PMID: 24881819.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    15. Rac2 controls tumor growth, metastasis and M1-M2 macrophage differentiation in vivo. PLoS One. 2014; 9(4):e95893. Joshi S, Singh AR, Zulcic M, Bao L, Messer K, Ideker T, Dutkowski J, Durden DL. PMID: 24770346.
      View in: PubMed   Mentions: 30     Fields:    Translation:AnimalsCells
    Shweta's Networks
    Concepts (126)
    Derived automatically from this person's publications.
    _
    Co-Authors (13)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _